Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Circulating Tumor Cells: A Useful Predictor Of Treatment Efficacy In Metastatic Breast Cancer.
M. Liu, P. Shields, R. Warren, Philip Cohen, M. Wilkinson, Y. Ottaviano, Suman Rao, J. Eng-Wong, F. Seillier-Moiseiwitsch, A. Noone, C. Isaacs
Published 2009 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
PURPOSE Five or more circulating tumor cells (CTCs) per 7.5 mL of blood predicts for poorer progression-free survival (PFS) in patients with metastatic breast cancer (MBC). We conducted a prospective study to demonstrate that CTC results correlate strongly with radiographic disease progression at the time of and in advance of imaging. PATIENTS AND METHODS Serial CTC levels were obtained in patients starting a new treatment regimen for progressive, radiographically measurable MBC. Peripheral blood was collected for CTC enumeration at baseline and at 3- to 4-week intervals. Clinical outcomes were based on radiographic studies performed in 9- to 12-week intervals. RESULTS Sixty-eight patients were evaluable for the CTC-imaging correlations, and 74 patients were evaluable for the PFS analysis. Median follow-up was 13.3 months. A statistically significant correlation was demonstrated between CTC levels and radiographic disease progression in patients receiving chemotherapy or endocrine therapy. This correlation applied to CTC results obtained at the time of imaging (odds ratio [OR], 6.3), 3 to 5 weeks before imaging (OR, 3.1), and 7 to 9 weeks before imaging (OR, 4.9). Results from analyses stratified by type of therapy remained statistically significant. Shorter PFS was observed for patients with five or more CTCs at 3 to 5 weeks and at 7 to 9 weeks after the start of treatment. CONCLUSION We provide, to our knowledge, the first evidence of a strong correlation between CTC results and radiographic disease progression in patients receiving chemotherapy or endocrine therapy for MBC. These findings support the role of CTC enumeration as an adjunct to standard methods of monitoring disease status in MBC.
This paper references
Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival
D. Hayes (2006)
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
M. Cristofanilli (2005)
Cancer statistics, 2000
R. Greenlee (2000)
Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer.
T. Bauernhofer (2005)
Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer
G. Budd (2006)
[Cancer cells in the circulating blood; a clinical study on the occurrence of cancer cells in the peripheral blood and in venous blood draining the tumour area at operation].
Engell Hc (1955)
Circulating tumor cells in the management of metastatic breast cancer patients
R. Beveridge (2007)
Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen‐receptor status and predicts for poor prognosis
J. Gaforio (2003)
Carcinocythemia (carcinoma cell leukemia). An acute leukemia-like picture due to metastatic carcinoma cells.
R. W. Carey (1976)
Longitudinal data analysis using generalized linear models
K. Liang (1986)
Circulating Cancer Cells in Peripheral Blood
N. Rodríguez-Salas (2000)
Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases
W. Allard (2004)
Circulating tumor cells and serum tumor biomarkers in small cell lung cancer.
P. Ma (2003)
Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System
S. Riethdorf (2007)
Carcinocythemia as the single extension of breast cancer: report of a case and review of the literature.
S. Séronie-Vivien (2001)
Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer.
P. Thiesse (1997)
Detection of circulating tumor cells and micrometastases in Stage II, III, and IV breast cancer patients utilizing cytology and immunocytochemistry
P. Fetsch (2000)
Immunocytodiagnosis of carcinocythemia in disseminated breast cancer.
Yam Lt (1987)
Small cell carcinocythemia.
C. C. Sile (1999)
Peripheral blood tumor cell load reflects the clinical activity of the disease in patients with carcinoma of the breast.
L. W. Terstappen (2000)
Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications.
F. Nolè (2008)
Carcinocythemia (carcinoma cell leukemia) due to metastatic carcinoma of the breast. Report of a case
R. Myerowitz (1977)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
M. Cristofanilli (2004)
Detection and isolation of circulating tumor cells in urologic cancers: a review.
R. Loberg (2004)
Carcinocythemia (carcinoma cell leukemia). Report of two cases with english literature review
M. V. Gallivan (1984)
Molecular Detection of Circulating Cancer Cells
B. Molnár (2003)
RT‐PCR‐Based Detection of Occult Disseminated Tumor Cells in Peripheral Blood and Bone Marrow of Patients with Solid Tumors: An Overview
A. Zippelius (2000)
Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors.
T. Pelkey (1996)
Cancer Statistics, 2008
A. Jemal (2008)
Molecular characterization of minimal residual cancer cells in patients with solid tumors.
B. Böckmann (2001)
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
Detection and characterization of carcinoma cells in the blood.
E. Racila (1998)
This paper is referenced by
Ex vivo culture of circulating tumor cells using magnetic force‐based coculture on a fibroblast feeder layer
S. Yamamoto (2016)
Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer
Maria A Papadaki (2018)
Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver
J. Kaifi (2015)
High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.
J.-Y. Pierga (2012)
Immunomagnetic separation technologies.
Astrid E L M Hoeppener (2012)
Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility
A. M. Berghuis (2017)
Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer
T. Naito (2012)
Perioperative circulating tumor cell detection: Current perspectives
J. Kaifi (2016)
Microfluidic blood cell sorting: now and beyond.
Zeta Tak For Yu (2014)
Determining tissue origin of circulating epithelial cells (CEC) in patients with differentiated thyroid cancer by real-time PCR using thyroid mRNA probes.
Sarah Sorg (2015)
Minimal residual disease and circulating tumor cells in breast cancer
M. Ignatiadis (2011)
Prognostic and Predictive Role of Circulating Tumor Cells in Breast Cancer
M. Mego (2014)
New Approach for Interpreting Changes in Circulating Tumour Cells (CTC) for Evaluation of Treatment Effect in Metastatic Breast Cancer
P. Horn (2014)
Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance
Yun-fan Sun (2011)
Insights into deep learning methods with application to cancer imaging
N.R.F. Huttinga (2017)
Clinical implications of the detection of circulating tumor cells in breast cancer patients.
M. Banys (2012)
KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer
Yuurin Kondo (2017)
IDENTIFYING CIRCULATING TUMOR CELLS IN BREAST CANCER WITH DATA MINING ALGORITHMS BY USING MICROARRAY
Mythili Balu (2016)
Solidifying liquid biopsies: can circulating tumor cell monitoring guide treatment selection in breast cancer?
A. Bardia (2014)
Nanotechnology-Based Strategies for Early Cancer Diagnosis Using Circulating Tumor Cells as a Liquid Biopsy
Qinqin Huang (2018)
Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine
Andreia de Albuquerque (2012)
Tocotrienol and cancer metastasis
Leanne De Silva (2016)
Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients.
M. Magbanua (2013)
Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker.
S. F. Moussavi-Harami (2014)
Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients: properties, enrichment, and potential targets
C. Schindlbeck (2016)
Title RNA-Seq of Circulating Tumor Cells in Stage II-III Breast Cancer
J. Lang (2018)
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement
T. Franchina (2012)
Using aptamers to visualize and capture cancer cells
Y. Pu (2010)
Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients
M. Thalgott (2015)
Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy.
M. Magbanua (2020)
Circulating stem cell–like epithelial cell adhesion molecule–positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection
Yunfan Sun (2013)
Novel approaches in cancer management with circulating tumor cell clusters
P. Rostami (2019)See more